KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial.

Nicholas van As, Binnaz Yasar, Clare Griffin, Jaymini Patel, Alison C Tree, Peter Ostler, Hans van der Voet, Daniel Ford, Shaun Tolan, Paula Wells, Rana Mahmood, Mathias Winkler, Andrew Chan, Alan Thompson, Chris Ogden, Olivia Naismith, Julia Pugh, Georgina Manning, Stephanie Brown, Stephanie Burnett, Emma Hall

Eur Urol 86(6) 566-576

PMID39266383
PMCID-
DOI10.1016/j.eururo.2024.08.030
发表日期2024-09-12
入排依据:The record describes a Phase III randomized trial in prostate cancer, but it compares two non-drug interventions (prostatectomy vs. stereotactic radiotherapy) and does not report a time-to-event efficacy endpoint; primary outcomes are patient-reported quality of life metrics.
摘要

摘要

BACKGROUND AND OBJECTIVE: Randomised data on patient-reported outcomes (PROs) for stereotactic body radiotherapy (SBRT) and prostatectomy in localised prostate cancer are lacking. PACE-A compared patient-reported health-related quality of life after SBRT with that after prostatectomy. METHODS: PACE is a phase 3 open-label, randomised controlled trial. PACE-A randomised men with low- to intermediate-risk localised prostate cancer to SBRT or prostatectomy (1:1). Androgen deprivation therapy (ADT) was not permitted. The coprimary outcomes were the Expanded Prostate Index Composite (EPIC-26) number of absorbent urinary pads required daily and bowel domain score at 2 yr. The secondary endpoints were clinician-reported toxicity, sexual functioning, and other PROs. KEY FINDINGS AND LIMITATIONS: In total, 123 men were randomised (60 undergoing prostatectomy and 63 SBRT) from August 2012 to February 2022. The median follow-up time was 60.7 mo. The median age was 65.5 yr and the median prostate-specific antigen (PSA) value 7.9 ng/ml; 92% had National Comprehensive Cancer Network (NCCN) intermediate-risk disease. Fifty participants received prostatectomy and 60 received SBRT. At 2 yr, 16/32 (50%) prostatectomy and three of 46 (6.5%) SBRT participants used one or more urinary pads daily (p < 0.001; 15 and two, respectively, used one pad daily); the estimated difference was 43% (95% confidence interval [CI]: 25%, 62%). At 2 yr, bowel scores were better for prostatectomy (median [interquartile range] 100 [100-100]) than for SBRT (87.5 [79.2-100]; p < 0.001), with an estimated mean difference of 8.9 between these (95% CI: 4.2, 13.7); sexual scores were worse for prostatectomy (18 [13.8-40.3]) than for SBRT (62.5 [32.0-87.5]). The limitations were slow recruitment and incomplete 2-yr PRO response rates. CONCLUSIONS AND CLINICAL IMPLICATIONS: SBRT was associated with less patient-reported urinary incontinence and sexual dysfunction, and slightly more bowel bother than prostatectomy. These randomised data should inform treatment decision-making for patients with localised, intermediate-risk prostate cancer.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。